-

Aesthetic Industry Leader Rob Hubert Announced as Chief Revenue Officer for Lynch Regenerative Medicine

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiary LRM Aesthetics, Inc. (LRMA), announced today that Rob Hubert will serve as Chief Revenue Officer (CRO) across both companies, effective immediately. Hubert will report directly to Dr. Samuel Lynch, Founder and CEO of LRM.

Hubert, who has served as a Strategic Advisor to LRM and LRMA for the past 18 months, brings more than 21 years of aesthetic business experience in sales and management. He previously served as Vice President of Sales at Allergan Aesthetics.

“Rob’s depth and breadth of experience in the aesthetics market is ideal to drive continued growth for LRMA’s groundbreaking lead product, ariessence pure PDGF+™, which is one of the hottest new products in aesthetics,” said Lynch. “He will also serve a critical role in helping guide strategy for the many new aesthetic and wound-healing products under development at LRM.”

Hubert is a graduate of the United States Naval Academy who served seven years in the U.S. Navy as a Surface Warfare Officer.

About Lynch Regenerative Medicine, LLC.

Lynch Regenerative Medicine, LLC., is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage, and our decades-long commitment to safe and effective regenerative products of the highest quality, to deliver exceptional results for our customers and their patients and thereby redefine the future of aesthetic regenerative medicine. The company was founded in 2023 and is based in Franklin, Tennessee.

Contacts

Nancy Rocco
n.rocco@lynchregen.com
(888) 576-7343

Lynch Regenerative Medicine, LLC.


Release Versions

Contacts

Nancy Rocco
n.rocco@lynchregen.com
(888) 576-7343

More News From Lynch Regenerative Medicine, LLC.

Lynch Regenerative Medicine Hires Hee as Chief Scientific Officer

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiaries LRM Aesthetics, Inc. (LRMA), and LRM WoundCare, Inc. (LRMW), announced today that Charlie Hee, Ph.D., will join its team as Chief Scientific Officer (CSO) across all companies, effective immediately. Dr. Hee is an experienced translational scientist and strategic leader, with more than 20 years of industry and research experience. Trained in tissue engineering, with a doctorate from the...

Lynch Regenerative Medicine Acquires REGRANEX® Gel and Exclusive Rights to Use Recombinant Pure PDGF for Soft Tissue Rejuvenation and Regeneration

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) announced today that it has acquired exclusive rights to REGRANEX® gel and recombinant purified platelet-derived growth factor (PDGF) from Smith & Nephew, Inc., for use in skin rejuvenation and regeneration as well as other soft tissue wound healing and tissue regeneration applications. PDGF is the first and only pure recombinant growth factor to have received approval from the U.S. Food and Drug Administration (FDA)...

Tod Reed Joins Lynch Regenerative Medicine as Strategic Advisor

FRANKLIN, Tenn.--(BUSINESS WIRE)--Tod Reed will join Lynch Regenerative Medicine, LLC (LRM) as a Senior Strategic Advisor. Reed recently retired as the Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics, an Abbvie company. Reed brings 37 years of experience with Allergan to the LRM team, including more than 20 years in aesthetic and regenerative medicine. During his tenure at Allergan Aesthetics, Reed was responsible for helping build the largest sales organization in...
Back to Newsroom